Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Case description: August 11, 2009 first two visits
- Case description: August 17, third visit
- Dengue outbreak timeline
- Florida Keys trial
- Key Haven
- Oxitec’s genetically engineered mosquitoes
- The “silent expansion” of disease-causing vectors
- FDA review and “finding of no significant impact”
- Methods
- Findings (1)
- Ecological implications
- Human health (1)
- Human health (2)
- Genetically-modified organisms
- Mistrust of government
- Mistrust of industry
- Findings (2)
- Relationships among themes
- Georeferenced attitudes to GM mosquitoes
- Public response to GM mosquitoes trial
- Novel vector control methods deployed in California
- California attitudes and exposure to Ae. aegypti
- FDA publishes FONSI
- General election, November 8, 2016
- FKMCD approves agreement with Oxitec
- Ongoing use in other countries
- Final remarks
- Public health ethics
- Acknowledgements
Topics Covered
- Recent transmissions of mosquito-borne disease
- Oxitec proposal of a Florida Keys trial of genetically engineered mosquitoes
- FDA “Finding of No Significant Impact”
- FDA public comments analyzed
- Themes: ecological implications; human health; concerns about genetically modified organisms generally; government and industry mistrust
- Georeferenced attitudes to genetically engineered mosquitoes
- Results of Florida’s non-binding referendum
- Importance of public trust to successful public health interventions
Talk Citation
Bloss, C. (2018, April 30). Public response to a proposed field trial of genetically engineered mosquitoes in the United States [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/ZCPW6343.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Cinnamon Bloss has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Public response to a proposed field trial of genetically engineered mosquitoes in the United States
Published on April 30, 2018
25 min
Other Talks in the Series: Gene-Drives and Active Genetics
Transcript
Please wait while the transcript is being prepared...
0:00
It's a pleasure to be able to present this work today.
My name is Cinnamon Bloss.
I am an Associate Professor at the University of California, San Diego.
The title of my talk is Public Response to
a Proposed Field Trial of Genetically Engineered Mosquitoes in the United States.
This is a case study analysis that I'll be speaking about today.
0:20
So, on August 11th,
2009 in Rochester, New York,
a 34-year-old female showed up at her primary care physician with a headache,
fever and was ended up being treated for a urinary tract infection.
Two days later, she still didn't feel right.
She came back to her physician with a worsening headache.
She had lightheadedness, retro orbital eye pain which is sort of a neurological red flag.
She ended up being referred to the emergency room
and at that time had a negative CAT scan and a lumbar puncture.
Over the course of her short stay in the emergency room,
her lightheadedness resolved and she was sent home after about a seven-hour stay there.
1:05
On August 17th, she came back again to her position for a third visit saying,
"I just don't feel right."
At that point, her physician learned that she
had just returned from a one-week trip to Key West,
Florida where she had received multiple mosquito bites.
At that point, an infectious disease specialist was brought in and
a serum test that they did at that time was sent to
the CDC and found to be positive for dengue fever.
1:35
So she was considered patient zero for
a dengue outbreak that occurred in Florida beginning at that time.
On August 31st, the second patient emerged,
a local Florida resident who is positive for dengue.
At that point, the Florida Department of Public Health did what's
called a serosurvey and randomly tested households in Florida.
Of about 240 people that were tested,
13 or about five percent had evidence of recent dengue infection.
In a number of months later,
by December of 2010,
there were a total of 88 confirmed cases of dengue associated with this outbreak.
This was the first instance of
dengue cases acquired in the continental United States outside of
the Texas-Mexico border since 1945 and
the first locally acquired cases in Florida since 1934.
Hide